Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Peter Gale

Showing results (361-370 of 373) with videos related to

Pageof 38
Sort By:
Transplantation and Cellular Therapy|October 3, 2020
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research StudyNelli Bejanyan, Meijie Zhang, Khalid Bo-Subait, et al.
Blood Advances|May 5, 2019
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemiaRohtesh S Mehta, Shernan G Holtan, Tao Wang, et al.
Blood Advances|September 22, 2021
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AMLKamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2020
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCTRohtesh S Mehta, Shernan G Holtan, Tao Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 6, 2018
Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell TransplantationMaxim Norkin, Bronwen E Shaw, Ruta Brazauskas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2020
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic SyndromesAziz Nazha, Zhen-Huan Hu, Tao Wang, et al.
Blood Advances|May 13, 2020
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseasesJustine M Kahn, Ruta Brazauskas, Heather R Tecca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2019
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research ReportHaesook T Kim, Kwang Woo Ahn, Zhen-Huan Hu, et al.
Bone Marrow Transplantation|September 29, 2021
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysisAntonio M Jimenez Jimenez, Marcos De Lima, Krishna V Komanduri, et al.
Bone Marrow Transplantation|April 17, 2021
Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantationMary-Elizabeth Percival, Hai-Lin Wang, Mei-Jie Zhang, et al.
Pageof 38

Showing results (361-370 of 373) with videos related to

Sort By:
Pageof 38
Transplantation and Cellular Therapy|October 3, 2020
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research StudyNelli Bejanyan, Meijie Zhang, Khalid Bo-Subait, et al.
Blood Advances|May 5, 2019
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemiaRohtesh S Mehta, Shernan G Holtan, Tao Wang, et al.
Blood Advances|September 22, 2021
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AMLKamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2020
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCTRohtesh S Mehta, Shernan G Holtan, Tao Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 6, 2018
Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell TransplantationMaxim Norkin, Bronwen E Shaw, Ruta Brazauskas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2020
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic SyndromesAziz Nazha, Zhen-Huan Hu, Tao Wang, et al.
Blood Advances|May 13, 2020
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseasesJustine M Kahn, Ruta Brazauskas, Heather R Tecca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2019
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research ReportHaesook T Kim, Kwang Woo Ahn, Zhen-Huan Hu, et al.
Bone Marrow Transplantation|September 29, 2021
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysisAntonio M Jimenez Jimenez, Marcos De Lima, Krishna V Komanduri, et al.
Bone Marrow Transplantation|April 17, 2021
Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantationMary-Elizabeth Percival, Hai-Lin Wang, Mei-Jie Zhang, et al.
Pageof 38